Read the latest updates from MitoRx Therapeutics

• • Press Release
  • Posted 27 May, 2026

  MitoRx Therapeutics to present new preclinical data on MTRX31 at the American Diabetes Association’s 2026 Scientific Sessions

  Read More
• • Press Release
  • Posted 17 November, 2025

  MitoRx Therapeutics raises GBP 5.5 million pre-series A round to advance a next generation obesity treatment

  Read More
• • Press Release
  • Posted 16 September, 2025

  MitoRx Therapeutics presents additional muscle preservation and liver-fat clearance data in obesity at EASD

  Read More
• • In The Media
  • Posted 29 August, 2025

  Rethinking Weight Loss Treatments – The Medicine Maker

  Read More
• • Publication
  • Posted 26 August, 2025

  Characterization of Myo4 in the murine diet-induced obesity model: a first-in-class anti-obesogenic muscle-preserving small molecule metabolic modulator

  Read More
• • In The Media
  • Posted 7 July, 2025

  New data backs Myo4 for obesity treatment – Drug Target Review

  Read More
• • In The Media
  • Posted 1 July, 2025

  MitoRx Takes Aim At GLP-1 Limitations – By Jo Shorthouse

  Read More
• • Press Release
  • Posted 23 June, 2025

  MitoRx Therapeutics presents data demonstrating restoration of insulin sensitivity, building on its muscle preserving weight loss approach in obesity

  Read More
• • Publication
  • Posted 20 June, 2025

  Myo4, a First-in-Class Anti-obesogenic and Muscle Preserving Small Molecule Metabolic Modulator

  Read More
• • Press Release
  • Posted 14 May, 2025

  MitoRx Therapeutics presents exciting new data showing weight loss with muscle preservation for novel small molecule Myo4 targeting obesity

  Read More